Maternal Immunomodulation Therapy for Prevention of Preterm Birth and Prematurity-Related Morbidity: The New Era of Immuno-Perinatology

Publisher: Bentham Science Publishers

E-ISSN: 1873-4286|23|40|6125-6131

ISSN: 1381-6128

Source: Current Pharmaceutical Design, Vol.23, Iss.40, 2018-02, pp. : 6125-6131

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Preterm birth and associated prematurity-related morbidity can significantly affect neonatal health andoutcomes. While the mechanisms of preterm labor are yet to be fully understood, there is a need for prenataltherapeutic interventions to treat these conditions. As it is recognized from literature, the immune mechanismsresponsible for preterm labor may be different from those responsible for prematurity-related conditions in theneonate. Differentiating the mechanisms for these two processes is yet to be addressed, and steps need to be takento move forward the new field of immune-perinatology. One class of treatment is immunotherapy to target theimmune modulators involved in preterm labor and its sequelae. This paper focuses on reviewing existing literatureon studying the efficacy of maternal immunomodulatory therapy on preventing preterm birth and prematurity-related adverse outcomes in the newborn.